Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | USP1 | O94782 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15715964 | 0.90 | USP2 (0.42) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL21216177 | 0.90 | USP2 (0.42) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL19459465 | 0.90 | USP2 (0.42) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL10172533 | 0.88 | USP2 (0.50) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL27301648 | 0.88 | USP2 (0.44) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL1744071 | 0.87 | USP2 (0.46) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL18693034 | 0.87 | USP2 (0.49) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL1702211 | 0.87 | USP2 (0.38) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL15368794 | 0.85 | USP2 (0.47) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL31726226 | 0.85 | USP2 (0.47) | USP2SMN1; SMN2NR1H2HPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 416 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116884-A1 | PROTAC CHIMERIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO LTD (CN) | 2026-04-30 | — | — | US | disclosed |
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2026-01-20 | — | — | US | disclosed |
| EP-4635956-A1 | PROTAC CHIMERIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) | 2025-10-22 | — | — | EP | disclosed |
| EP-4631940-A1 | COMPOUND TARGETING PAN-KRAS PROTEIN DEGRADATION AGENT AND USE THEREOF | Betta Pharmaceuticals Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| EP-4626555-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| WO-2007002884-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1517894-B1 | N-BENZYL-3-PHENYL-3-HETEROCYCLYL-PROPIONAMIDE COMPOUNDS AS TACHYKININ ANTAGONISTS AND/OR SEROTONIN REUPTAKE INHIBITORS | GLAXO GROUP LTD (GB) | 2006-09-06 | — | — | EP | disclosed |
| US-20060058348-A1 | N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/or serotonin reuptake inhibitors | GLAXO GROUP LIMITED (GB) | 2006-03-16 | — | — | US | disclosed |
| US-6995144-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-20050245527-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| CN-1630650-A | Nitrogen-containing heterocyclic compound and drug containing same | EISAI CO LTD (JP) | 2005-06-22 | — | — | CN | disclosed |
| EP-1505067-A1 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-09 | — | — | EP | disclosed |
| EP-1484327-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | Eisai Co., Ltd. (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20040167224-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528773-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, GAA | USP2 3193/4885SMN1; SMN2 2631/4885NR1H2 1484/4885 |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | USP2 730/4885SMN1; SMN2 3384/4885NR1H2 137/4885 |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | USP2 1951/4885SMN1; SMN2 4687/4885NR1H2 1310/4885 |
| US-20260116884-A1 | PROTAC CHIMERIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | CXCR1, TXK, CXCR4 | USP2 4142/4885SMN1; SMN2 4103/4885NR1H2 128/4885 |
| US-20060058348-A1 | N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/or serotonin reuptake inhibitors | HTR7, OPRL1, HCRTR1 | USP2 3115/4885SMN1; SMN2 3996/4885NR1H2 502/4885 |
| US-20040167224-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | NQO1, CBR1, NOX1 | USP2 3522/4885SMN1; SMN2 1325/4885NR1H2 252/4885 |
| US-20050245527-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | XDH, NQO1, CYP1A1 | USP2 3639/4885SMN1; SMN2 1451/4885NR1H2 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.